Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
7 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
26 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Mar 24
424B5
Prospectus supplement for primary offering
13 Mar 24
8-K
Results of Operations and Financial Condition
11 Mar 24
424B5
Prospectus supplement for primary offering
11 Mar 24
8-K
Departure of Directors or Certain Officers
20 Feb 24
EFFECT
Notice of effectiveness
9 Jan 24
424B4
Prospectus supplement with pricing info
8 Jan 24
8-K
Other Events
4 Jan 24
CORRESP
Correspondence with SEC
4 Jan 24
UPLOAD
Letter from SEC
3 Jan 24
S-3
Shelf registration
29 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
8-K
Other Events
12 Sep 23
8-K
Regulation FD Disclosure
24 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
8 Aug 23
424B5
Prospectus supplement for primary offering
28 Jun 23
8-K
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
28 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4 May 23
8-K
Departure of Directors or Certain Officers
1 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
8-K
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
19 Apr 23
8-K
Other Events
28 Mar 23
424B5
Prospectus supplement for primary offering
27 Mar 23
S-8
Registration of securities for employees
23 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
23 Mar 23
Latest ownership filings
4
John Brendan Doyle
3 May 24
4
Lisa Ricciardi
14 Mar 24
4
John Brendan Doyle
20 Feb 24
4
Anthony Caggiano
20 Feb 24
4
Lisa Ricciardi
20 Feb 24
4
Anthony Caggiano
9 Feb 24
4
Lisa Ricciardi
9 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
PATHSTONE FAMILY OFFICE, LLC
19 Jan 24
SC 13D/A
BIOS Memory SPV I, LP
13 Nov 23
3
Initial statement of insider ownership
13 Nov 23
4
Leslie W. Kreis
13 Nov 23
4
Aaron G.L. Fletcher
13 Nov 23
4
Leslie W. Kreis
13 Jun 23
4
Aaron G.L. Fletcher
13 Jun 23
4
Brett P Monia
13 Jun 23
4
Peggy Wallace
13 Jun 23
4
ELLEN B RICHSTONE
13 Jun 23
4
Jack A. Khattar
13 Jun 23
4
John Brendan Doyle
3 May 23
3
John Brendan Doyle
3 May 23
SC 13G/A
HIRSCHMAN ORIN
15 Feb 23
4
Anthony Caggiano
7 Feb 23
4
Lisa Ricciardi
7 Feb 23
SC 13D/A
BIOS Memory SPV I, LP
5 Dec 22
4
ELLEN B RICHSTONE
29 Nov 22
4
Aaron G.L. Fletcher
29 Nov 22
4
Leslie W. Kreis
29 Nov 22
SC 13G
HIRSCHMAN ORIN
18 Nov 22
4
Aaron G.L. Fletcher
17 Nov 22
4
Leslie W. Kreis
17 Nov 22
4
Lisa Ricciardi
16 Nov 22
4
Peggy Wallace
16 Nov 22
4
Aaron G.L. Fletcher
16 Nov 22
4
Leslie W. Kreis
16 Nov 22
4
Change in insider ownership
29 Sep 22
4
Peggy Wallace
29 Sep 22
3
Andrew J. Einhorn
15 Aug 22
4/A
Aaron G.L. Fletcher
30 Jun 22
4/A
Brett P Monia
23 Jun 22